BETACONNECT自动注射器引入前后干扰素β-1b和干扰素β-1a依从性的真实世界评估：一项回顾性队列研究
Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT Autoinjector: A Retrospective Cohort Study.
作者信息
Butler Oisín, Heeg Simone, Holl Katsiaryna, Frenz Ann-Kathrin, Wicklein Eva-Maria, Rametta Mark, Yeo Sandy
机构信息
Medical Affairs and Pharmacovigilance, Pharmaceuticals, RWE Strategy & Outcomes Data Generation, Bayer AG, Building P300, 13342, Berlin, Germany.
Research and Development, Bayer AG, Berlin, Germany.
出版信息
Drugs Real World Outcomes. 2021 Sep;8(3):359-367. doi: 10.1007/s40801-021-00248-5. Epub 2021 Apr 29.
BACKGROUND
Both interferon beta-1b (IFN-β-1b) and interferon beta-1a (IFN-β-1a) are immunomodulators that require regular subcutaneous self-administration by patients with multiple sclerosis (MS). However, no electronic autoinjector is available for IFN-β-1a in the US.
OBJECTIVE
This retrospective cohort study investigated adherence to two subcutaneous disease-modifying therapies, IFN-β-1b and IFN-β-1a, during two periods (before and after the introduction of the BETACONNECT autoinjector for IFN-β-1b).
PATIENTS AND METHODS
Data were evaluated from the MarketScan database for adults in the US with an MS diagnosis and a medical claim for subcutaneous IFN-β-1b or IFN-β-1a, either before (October 2013-September 2015) or after the introduction of BETACONNECT (October 2016-September 2018). Patient populations were propensity-score matched by demographic and clinical characteristics. Persistence was recorded, and adherence was evaluated by medication possession ratio (MPR).
RESULTS
The study included 196 IFN-β-1b and 365 IFN-β-1a people with MS (PwMS) (pre-BETACONNECT period), and 126 IFN-β-1b and 223 IFN-β-1a PwMS (post-BETACONNECT period). In the pre-BETACONNECT period, the proportion with at least 80% MPR was higher for IFN-β-1a (90%) than for IFN-β-1b (83%), but in the post-BETACONNECT period the proportion with ≥ 80% MPR was higher for IFN-β-1b (92%) than for IFN-β-1a (86%). In the pre-BETACONNECT period, median persistence (in days) was higher for IFN-β-1a (199) than for IFN-β-1b (152), while in post-BETACONNECT period persistence was higher for IFN-β-1b (327) than for IFN-β-1a (229).
CONCLUSIONS
Following the introduction of BETACONNECT, this exploratory study suggested that PwMS taking IFN-β-1b were more adherent compared with those taking IFN-β-1a, with higher persistence, and more than 90% reached 80% MPR, a threshold commonly used to define good adherence.
背景
干扰素β-1b（IFN-β-1b）和干扰素β-1a（IFN-β-1a）均为免疫调节剂，多发性硬化症（MS）患者需要定期自行皮下注射。然而，在美国，尚无用于IFN-β-1a的电子自动注射器。
目的
这项回顾性队列研究调查了在两个时期（IFN-β-1b的BETACONNECT自动注射器推出之前和之后）两种皮下疾病改善疗法IFN-β-1b和IFN-β-1a的依从性。
患者和方法
数据来自美国MarketScan数据库中诊断为MS且有皮下注射IFN-β-1b或IFN-β-1a医疗索赔的成年人，数据收集时间为BETACONNECT推出之前（2013年10月至2015年9月）或之后（2016年10月至2018年9月）。根据人口统计学和临床特征对患者群体进行倾向评分匹配。记录持续用药情况，并通过药物持有率（MPR）评估依从性。
结果
该研究纳入了196例使用IFN-β-1b的MS患者（PwMS）和365例使用IFN-β-1a的PwMS（BETACONNECT推出前时期），以及126例使用IFN-β-1b的PwMS和223例使用IFN-β-1a的PwMS（BETACONNECT推出后时期）。在BETACONNECT推出前时期，MPR至少为80%的IFN-β-1a使用者比例（90%）高于IFN-β-1b使用者（83%），但在BETACONNECT推出后时期，MPR≥80%的IFN-β-1b使用者比例（92%）高于IFN-β-1a使用者（86%）。在BETACONNECT推出前时期，IFN-β-1a的中位持续用药天数（199天）高于IFN-β-1b（152天），而在BETACONNECT推出后时期，IFN-β-1b的持续用药天数（327天）高于IFN-β-1a（229天）。
结论
在引入BETACONNECT之后，这项探索性研究表明，与使用IFN-β-1a的PwMS相比，使用IFN-β-1b的PwMS依从性更高，持续用药时间更长，超过90%的人达到了80%的MPR，这是常用于定义良好依从性的阈值。
Zotero 插件